Holen Sie sich die Stockscreener-App
2.52
5.44%
0.13
Vorhandelsmarkt:
2.46
-0.06
-2.38%
Schlusskurs vom Vortag:
$2.39
Offen:
$2.4
24-Stunden-Volumen:
74,019
Relative Volume:
0.12
Marktkapitalisierung:
$12.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.309
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
+5.88%
1M Leistung:
+11.26%
6M Leistung:
+10.04%
1J Leistung:
-43.46%
1-Tages-Spanne:
$2.35
$2.54
1-Wochen-Bereich:
$2.3401
$2.54
52-Wochen-Spanne:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Vergleichen Sie PHIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.52 | 11.42M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
What analysts say about Phio Pharmaceuticals Corp. stockUnmatched market performance - Autocar Professional
Is Phio Pharmaceuticals Corp. a good long term investmentBreakout stock performance - jammulinksnews.com
Phio Pharmaceuticals Corp. Stock Analysis and ForecastAccelerated wealth expansion - jammulinksnews.com
What drives Phio Pharmaceuticals Corp. stock priceSuperior returns - jammulinksnews.com
Phio Pharmaceuticals shares rise 1.26% premarket after closing a public offering of 10,000,000 shares. - AInvest
Why Phio Pharmaceuticals Corp. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - Newser
What makes Phio Pharmaceuticals Corp. stock price move sharplySmart Growth Low Risk Picks - Newser
How Phio Pharmaceuticals Corp. stock performs during market volatilityFree Financial Group - Newser
Phio Pharmaceuticals Announces 2025 Annual Meeting Details - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 6.3% – Here’s Why - Defense World
Phio Pharma stock maintains buy rating as cancer trial advances - Investing.com
Phio’s PH-762 shows positive safety profile in fourth cohort trial - Investing.com
Breakthrough: Phio's Skin Cancer Treatment Shows Positive Results in Phase 1b Trial, CEO Details Progress - Stock Titan
Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes - TipRanks
Phio Pharmaceuticals Appoints Lisa Carson As Principal Financial OfficerSEC Filing - MarketScreener
Research Analysts Set Expectations for PHIO FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for PHIO Q2 Earnings? - Defense World
Phio Pharmaceuticals appoints new strategic and finance VPs By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints new strategic and finance VPs - Investing.com India
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - TradingView
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Phio Pharmaceuticals (NASDAQ:PHIO) Now Covered by HC Wainwright - Defense World
Phio Pharma (PHIO) Receives Buy Rating and $14 Price Target from HC Wainwright | PHIO Stock News - GuruFocus
H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating - Investing.com India
Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Pr - GuruFocus
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - The Globe and Mail
Why BioNTech Stock Soared Today - The Globe and Mail
Best Value Stocks to Buy for May 28th - The Globe and Mail
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):